Literature DB >> 27956431

Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.

Juan José Castón1,2, Álvaro De la Torre3, Isabel Ruiz-Camps4, María Luisa Sorlí5, Vicente Torres6, Julián Torre-Cisneros7,2,8.   

Abstract

Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosa; ceftolozane-tazobactam; salvage therapy

Mesh：

Substances：

Year:  2017        PMID： 27956431      PMCID： PMC5328537          DOI： 10.1128/AAC.02136-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.

Authors:  Gurudatt Chandorkar; Jennifer A Huntington; Mark H Gotfried; Keith A Rodvold; Obiamiwe Umeh
Journal:  J Antimicrob Chemother       Date:  2012-07-06       Impact factor: 5.790

2.  In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.

Authors:  Marta Tato; María García-Castillo; Ana Moreno Bofarull; Rafael Cantón
Journal:  Int J Antimicrob Agents       Date:  2015-08-10       Impact factor: 5.283

3.  Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).

Authors:  Florian M Wagenlehner; Obiamiwe Umeh; Judith Steenbergen; Guojun Yuan; Rabih O Darouiche
Journal:  Lancet       Date:  2015-04-27       Impact factor: 79.321

4.  Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.

Authors:  Gabriel Cabot; Sebastian Bruchmann; Xavier Mulet; Laura Zamorano; Bartolomé Moyà; Carlos Juan; Susanne Haussler; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

Review 5.  Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: a narrative review for the clinician.

Authors:  Nihal Martis; Sylvie Leroy; Véronique Blanc
Journal:  J Infect       Date:  2014-03-11       Impact factor: 6.072

6.  Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.

Authors:  Gabriel Cabot; Alain A Ocampo-Sosa; Fe Tubau; María D Macia; Cristina Rodríguez; Bartolomé Moya; Laura Zamorano; Cristina Suárez; Carmen Peña; Luis Martínez-Martínez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

7.  Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).

Authors:  Helio S Sader; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  J Infect       Date:  2014-04-26       Impact factor: 6.072

Review 8.  Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.

Authors:  Jonathan C Cho; Mallory A Fiorenza; Sandy J Estrada
Journal:  Pharmacotherapy       Date:  2015-07-01       Impact factor: 4.705

9.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

10.  Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.

Authors:  Alberto Hernández-Tejedor; Carmen Débora Merino-Vega; Alfredo Martín-Vivas; Rafael Ruiz de Luna-González; Alberto Delgado-Iribarren; Ángeles Gabán-Díez; Ignacio Temprano-Gómez; Natalia de la Calle-Pedrosa; Ana Isabel González-Jiménez; Alejandro Algora-Weber
Journal:  Infection       Date:  2016-09-26       Impact factor: 3.553
View more
  19 in total

1.  A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection.

Authors:  Ana Fernández-Cruz; Natalia Alba; María Auxiliadora Semiglia-Chong; Belén Padilla; Gabriela Rodríguez-Macías; Mi Kwon; Emilia Cercenado; Esther Chamorro-de-Vega; Marina Machado; Laura Pérez-Lago; Darío García de Viedma; José Luis Díez Martín; Patricia Muñoz
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder.

Authors:  Aurélien Dinh; Benjamin Davido; Ruxandra Calin; Julie Paquereau; Clara Duran; Frédérique Bouchand; Véronique Phé; Emmanuel Chartier-Kastler; Martin Rottman; Jérôme Salomon; Patrick Plésiat; Anaïs Potron
Journal:  Spinal Cord Ser Cases       Date:  2017-05-11

3.  Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.

Authors:  Laura Escolà-Vergé; Carles Pigrau; Ibai Los-Arcos; Ángel Arévalo; Belen Viñado; David Campany; Nieves Larrosa; Xavier Nuvials; Ricard Ferrer; Oscar Len; Benito Almirante
Journal:  Infection       Date:  2018-03-28       Impact factor: 3.553

4.  Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.

Authors:  Sarah C J Jorgensen; Trang D Trinh; Evan J Zasowski; Abdalhamid M Lagnf; Samuel P Simon; Sahil Bhatia; Sarah M Melvin; Molly E Steed; Natalie A Finch; Taylor Morrisette; Sandy J Estrada; Joshua R Rosenberg; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.

Authors:  Morgan Hakki; James S Lewis
Journal:  Infection       Date:  2018-02-19       Impact factor: 3.553

Review 6.  Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?

Authors:  Lynn Nguyen; Joshua Garcia; Katherine Gruenberg; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2018-06-06       Impact factor: 3.725

Review 7.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

8.  Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.

Authors:  David M Livermore; Shazad Mushtaq; Daniele Meunier; Katie L Hopkins; Robert Hill; Rachael Adkin; Aiysha Chaudhry; Rachel Pike; Peter Staves; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

Review 9.  Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Infect Dis Ther       Date:  2021-07-18

Review 10.  Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence.

Authors:  Luca Gregorio Giaccari; Maria Caterina Pace; Maria Beatrice Passavanti; Francesca Gargano; Caterina Aurilio; Pasquale Sansone
Journal:  Life (Basel)       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.